Response to letter entitled: Re: Immune checkpoint blockade for patients with lung cancer and idiopathic pulmonary fibrosis

[1]  G. Raghu,et al.  The DIAMORFOSIS (DIAgnosis and Management Of lung canceR and FibrOSIS) survey: international survey and call for consensus , 2020, ERJ Open Research.

[2]  T. Yamanaka,et al.  A Phase 2 Study of Atezolizumab for Pretreated NSCLC With Idiopathic Interstitial Pneumonitis , 2020, Journal of Thoracic Oncology.

[3]  J. Ahn,et al.  Are there any ethnic differences in the efficacy and safety of immune checkpoint inhibitors for treatment of lung cancer? , 2020, Journal of thoracic disease.

[4]  M. Antoine,et al.  Interstitial Lung Disease Associated with Lung Cancer: A Case–Control Study , 2020, Journal of clinical medicine.

[5]  Y. Hosomi,et al.  Nivolumab for advanced non-small cell lung cancer patients with mild idiopathic interstitial pneumonia: A multicenter, open-label single-arm phase II trial. , 2019, Lung cancer.

[6]  M. Antoine,et al.  Lung cancer and interstitial lung disease: a literature review. , 2018, Journal of thoracic disease.

[7]  D. Lynch,et al.  Acute Exacerbation of Idiopathic Pulmonary Fibrosis. An International Working Group Report. , 2016, American journal of respiratory and critical care medicine.

[8]  S. Kudoh,et al.  Basis of acute exacerbation of idiopathic pulmonary fibrosis in Japanese patients. , 2008, American journal of respiratory and critical care medicine.

[9]  H. Kato,et al.  Interstitial lung disease in Japanese patients with lung cancer: a cohort and nested case-control study. , 2008, American journal of respiratory and critical care medicine.